Lambert-Eaton myasthenic syndrome (LEMS) is a neuromuscular junction disorder which may present as a paraneoplastic phenomenon or a primary autoimmune disorder. More than half of the cases are associated with small cell lung cancer (SCLC). The primary clinical manifestation is muscle weakness. The pathology is due to the generation of antibodies against voltage-gated calcium channels (VGCC) on presynaptic nerve terminals leading to a decrease in the neurotransmitter acetylcholine (ACh). This topic will review the pathogenesis, diagnostic testing, and treatment of Lambert-Eaton myasthenic syndrome.
Lambert-Eaton myasthenic syndrome is classified as paraneoplastic or non-paraneoplastic, also referred to as non-tumor Lambert-Eaton myasthenic syndrome (NT-LEMS). NT- LEMS occurs in the absence of malignancy. Sixty percent of patients with Lambert-Eaton myasthenic syndrome have an underlying tumor. Paraneoplastic Lambert-Eaton myasthenic syndrome is typically associated with small cell lung cancer (SCLC). Other malignancies that have been associated with Lambert-Eaton myasthenic syndrome include non-small cell and mixed lung carcinoma, prostate cancer, thymoma and lymphoproliferative disorders. Studies have indicated that the diagnosis of Lambert-Eaton myasthenic syndrome can precede a diagnosis of small cell lung cancer, ranging from up to 5 to 6 years. History of smoking is also considered a risk factor. The genetic association with HLA–B8–DR 3 haplotype is present in about 65% of young patients with NT–L EMS.
Lambert-Eaton myasthenic syndrome is a rare neuromuscular disorder, which is 46 times less prevalent than Myasthenia Gravis (MG). However, the annual incidence of Lambert-Eaton myasthenic syndrome was only 10 to 14 times lower than MG. The increased prevalence of MG compared to Lambert-Eaton myasthenic syndrome speaks to the poor prognosis and survival of Lambert-Eaton myasthenic syndrome specifically when associated with SCLC.
Sixty percent to 75% of the patients with Lambert-Eaton myasthenic syndrome were male compared to the female predilection seen in MG. The mean age of presentation associated with paraneoplastic Lambert-Eaton myasthenic syndrome was 58 years. In Lambert-Eaton myasthenic syndrome that was not associated with malignancy. The age and sex distribution were similar to that of MG, with a peak age of onset of 35 years and a second larger peak at 60 years. The Lambert-Eaton myasthenic syndrome without malignancy has a near-normal survival rate.
Lambert-Eaton myasthenic syndrome is a disorder of reduced acetylcholine release from the presynaptic nerve terminals due to antibodies to voltage-gated calcium channels in the presynaptic neuronal cell membrane.
The following is the normal mechanism of ACh release and interaction:
VGCC, a large transmembrane protein with multiple subunits has an important role as it mediates the influx of calcium into the nerve terminal. In Lambert-Eaton myasthenic syndrome, VGCC is reduced due to the IgG antibody-mediated cross-linking of the channels. More specifically, antibodies are directed towards the P/Q subtype of VGCC. 85% of patients with Lambert-Eaton myasthenic syndrome demonstrate antibodies against the P/Q type VGCC. Rarely, antibodies against the N-type VGCC has been found in malignancy-associated Lambert-Eaton myasthenic syndrome.
Autoimmunity with SCLC: In patients with Lambert-Eaton myasthenic syndrome associated with SCLC, the tumor tissue expresses VGCC. This expression of antigens on the tumor cells induces the autoantibody production, and the autoantibodies cross-react with presynaptic VGCC antigens.
Genetic predisposition: Non-tumor Lambert-Eaton myasthenic syndrome is associated with HLA-B8 (HLA - class I) and HLA -DR3 and -DQ2 (HLA class II). These HLA genotypes have also been associated with other autoimmune conditions including myasthenia gravis. Conversely, it is not seen in Lambert-Eaton myasthenic syndrome associated with SCLC.
The most frequent clinical manifestations of Lambert-Eaton myasthenic syndrome are proximal muscle weakness, autonomic dysfunction, and absent deep tendon reflexes. Symptoms are usually insidious in onset and progress more rapidly in SCLC-LEMS.
The presence of clinical features such as proximal muscle weakness associated with areflexia and autonomic dysfunction should prompt an evaluation for Lambert-Eaton myasthenic syndrome. The diagnosis of Lambert-Eaton myasthenic syndrome can be confirmed by the presence of P/Q-type VGCC along with electrodiagnostic studies.
Antibodies against the P/Q-type VGCC detected in a radioimmunoassay are present in approximately 85% to 95% of patients with Lambert-Eaton myasthenic syndrome. However, the presence of P/Q- type VGCC is not specific to Lambert-Eaton myasthenic syndrome as it has been associated with a number of neurological conditions and other autoimmune disorders. Less frequently (30% to 40%), antibodies against N-type VGCC are seen in Lambert-Eaton myasthenic syndrome. In addition, 64% of Lambert-Eaton myasthenic syndrome patients with SCLC also were found to have antibodies against SOX1, an immunogenic tumor antigen in SCLC with a 95% specificity.
The initial findings on electrodiagnostic testing described by Eaton and Lambert were a low CMAP (compound muscle action potential) amplitude at rest, a decremental response at low rates of repetitive nerve stimulation (RNS), and an incremental response at high-rate stimulation. These findings have largely been reproducible however varying findings have also been described.
Following high-frequency RNS or post-exercise, a significant incremental response up to greater than 100% in CMAP amplitude is seen, however up to a 60% to 99 % increase is considered diagnostic.
Needle EMG can demonstrate unstable action potentials.
Single fiber electromyography (SFEMG) often shows significant jitter and transmission blocking that is characteristically improved at higher firing rates. SFEMG is more sensitive than RNS. However, RNS is more widely available and is useful in distinguishing between myasthenia graves and Lambert-Eaton myasthenic syndrome by demonstrating the post-exercise facilitation.
Screening for Malignancy
Due to the strong affiliation with malignancy, the diagnosis of Lambert-Eaton myasthenic syndrome should prompt an immediate and extensive search for underlying malignancy. A CT or MRI of the chest is the initial recommended imaging study. PET scan is also used for initial screening if CT is negative. If the initial evaluation is negative, screening for cancer should continue every 3 to 6 months for at least 2 years. Screening every 3 months is indicated for those patients who are at high risk whose DELTA-P score greater than 2 or with positive SOX antibodies which are associated with SCLC-LEMS. The Dutch-English LEMS Tumor Association Prediction (DELTA-P) score consists of variables such as the age of diagnosis and smoking history and is used to risk stratify the association with SCLC in patients with Lambert-Eaton myasthenic syndrome and guide the screening for underlying malignancy.
The initial treatment for the symptomatic management of Lambert-Eaton myasthenic syndrome with or without malignancy is geared towards increasing the levels of acetylcholine. Acetylcholinesterase inhibitors such as pyridostigmine (30 to 120 mg every 3 to 6 hours) are used for the treatment of weakness. However, the effects are not as marked as with patients with myasthenia gravis. Another therapeutic option is 3,4 -diaminopyridine (3,4- DAP). 3,4-DAP binds to VGCCs that lead to prolongation of depolarization of the action potential increase the open time of the VGCCs which leads to an increased presynaptic influx of calcium and increased ACh release.
For patients with refractory weakness, immunosuppression with IVIG as the first-line agent is recommended. Other suggested alternatives include prednisone, rituximab, azathioprine, or plasma exchange.
Differential Diagnosis of Lambert-Eaton myasthenic syndrome includes MG. The distinguishing features include areflexia, autonomic dysfunction and the phenomena of post-exercise facilitation present in Lambert-Eaton myasthenic syndrome. Myopathies remain an important differential in the diagnosis of Lambert-Eaton myasthenic syndrome. The absence of sensory symptoms helps to rule out polyneuropathy or polyradiculopathies.
The diagnosis and management of patients with Lambert Eaton myasthenia syndrome requires a multidisciplinay team because of the diverse presentation. The disorder is usually seen in the presence of a malignancy and hence the team should include an oncologist, surgeon, hematologist, ophthalmologist, neurologist, primary care provider and nurse practitioner. The initial treatment for the symptomatic management of Lambert-Eaton myasthenic syndrome with or without malignancy is geared towards increasing the levels of acetylcholine. For patients with refractory weakness, immunosuppression with IVIG as the first-line agent is recommended. Other suggested alternatives include prednisone, rituximab, azathioprine, or plasma exchange.
The prognosis for patients with this syndrome depends on the primary malignancy. With advanced cases, the prognosis is poor. However, if the primary malignancy is controlled, symptomatic improvement does occur over time but often full recovery is not possible. (Level V)
|||Kitanosono H,Motomura M,Tomita H,Iwanaga H,Iwanaga N,Irioka T,Shiraishi H,Tsujino A, [Paraneoplastic Cerebellar Degeneration with Lambert-Eaton Myasthenic Syndrome: A Report of an Effectively Treated Case and Systematic Review of Japanese Cases]. Brain and nerve = Shinkei kenkyu no shinpo. 2019 Feb; [PubMed PMID: 30718446]|
|||Mansukhani SA,Bothun E,Diehl NN,Mohney BG, Incidence and Ocular Features of Pediatric Myasthenias. American journal of ophthalmology. 2019 Jan 14; [PubMed PMID: 30653958]|
|||Nakatani Y,Tanaka N,Enami T,Minami S,Okazaki T,Komuta K, Lambert-Eaton Myasthenic Syndrome Caused by Nivolumab in a Patient with Squamous Cell Lung Cancer. Case reports in neurology. 2018 Sep-Dec; [PubMed PMID: 30627102]|
|||Montes-Chinea NI,Guan Z,Coutts M,Vidal C,Courel S,Rebelo AP,Abreu L,Zuchner S,Littleton JT,Saporta MA, Identification of a new SYT2 variant validates an unusual distal motor neuropathy phenotype. Neurology. Genetics. 2018 Dec; [PubMed PMID: 30533528]|
|||Dean S,McCracken J,Kosmider S,Herath D, Lambert-Eaton myasthenic syndrome developing post-diagnosis of small-cell lung cancer. Internal medicine journal. 2018 Dec; [PubMed PMID: 30518000]|
|||Hoffman BM,Zeid NA,Alam U,Caress JB, Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration. Multiple sclerosis and related disorders. 2019 Jan; [PubMed PMID: 30384197]|
|||Cetin H,Vincent A, Pathogenic Mechanisms and Clinical Correlations in Autoimmune Myasthenic Syndromes. Seminars in neurology. 2018 Jun; [PubMed PMID: 30011414]|
|||Bussat A,Langner-Lemercier S,Salmon A,Mouriaux F, Paraneoplastic syndromes in ophthalmology. Journal francais d'ophtalmologie. 2018 May; [PubMed PMID: 29784239]|
|||Kesner VG,Oh SJ,Dimachkie MM,Barohn RJ, Lambert-Eaton Myasthenic Syndrome. Neurologic clinics. 2018 May; [PubMed PMID: 29655456]|
|||Lorenzoni PJ,Kay CSK,Werneck LC,Scola RH, Lambert-Eaton myasthenic syndrome: the 60th anniversary of Eaton and Lambert's pioneering article. Arquivos de neuro-psiquiatria. 2018 Feb; [PubMed PMID: 29489969]|
|||Portaro S,Brizzi T,Sinicropi S,Cacciola A,De Cola MC,Bramanti A,Milardi D,Lupica A,Bramanti P,Toscano A,Rodolico C, Five years experience on 3,4-diaminopyridine phosphate in Lambert-Eaton syndrome: Case reports. Medicine. 2017 Sep; [PubMed PMID: 28930822]|
|||Schneider I,Kornhuber ME,Hanisch F, Long-term observation of incremental response and antibodies to voltage-gated calcium channels in patients with Lambert-Eaton myasthenic syndrome: two case reports. Journal of medical case reports. 2015 Mar 14; [PubMed PMID: 25885033]|